SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like Free radicals generated at a specific site in astrocytes may promote dementia November 4, 2025 Scientists reveal Homo erectus mastered desert survival one million years ago January 19, 2025 Robotic hip exoskeleton could be a promising avenue for stroke rehabilitation March 4, 2024